BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/5/2017 12:48:28 AM | Browse: 1053 | Download: 1687
 |
Received |
|
2017-08-01 01:02 |
|
Peer-Review Started |
|
2017-08-01 10:51 |
|
To Make the First Decision |
|
2017-08-30 02:52 |
|
Return for Revision |
|
2017-08-31 06:58 |
|
Revised |
|
2017-09-13 09:53 |
|
Second Decision |
|
2017-09-25 07:32 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2017-09-26 01:43 |
|
Articles in Press |
|
2017-09-26 01:43 |
|
Publication Fee Transferred |
|
2017-10-09 09:14 |
|
Edit the Manuscript by Language Editor |
|
2017-10-18 19:46 |
|
Typeset the Manuscript |
|
2017-10-31 03:50 |
|
Publish the Manuscript Online |
|
2017-11-05 00:48 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Cheng-Ming Li, Zhi-Chao Liu, You-Ting Bao, Xin-Dong Sun and Lin-Lin Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81402299 |
| Project of Postdoctoral Innovation of Shandong Province |
201501010 |
| Project of Postdoctoral Science Foundation of China |
2016M590640 |
|
| Corresponding Author |
Lin-Lin Wang, MD, PhD, Chief Doctor, Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, No. 440, Jiyan Road, Jinan 250117, Shandong Province, China. 13793187739@163.com |
| Key Words |
Anti-angiogenesis; Apatinib; Pancreatic cancer; Targeted therapy; Vascular endothelial growth factor receptor-2 |
| Core Tip |
As chemotherapy has limited efficacy in the treatment of advanced and metastatic pancreatic cancer, targeted therapy is becoming increasingly important in patients with pancreatic cancer. The case reported herein suggests that apatinib, a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, may be a promising and useful agent in the treatment of pancreatic cancer. |
| Publish Date |
2017-11-05 00:48 |
| Citation |
Li CM, Liu ZC, Bao YT, Sun XD, Wang LL. Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review. World J Gastroenterol 2017; 23(41): 7478-7488 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i41/7478.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i41.7478 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
